Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Japanese Journal of Clinical Oncology · 01.06.2024 · 54 (6) · 722-729
DOI: 10.1093/jjco/hyae031 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 14.03.2024. Verfasst von Shimpei Yamashita und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Wakayama Medical University, Wakayama, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Ipilimumab, Nivolumab, Kidney Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Objective
Lung immune prognostic index is based on derived neutrophil-to-lymphocyte ratio and lactate dehydrogenase level. Lung immune prognostic index has reported association with survival outcomes in patients with various malignancies undergoing treatment with immune checkpoint inhibitors. However, the prognostic impact of pre-treatment lung immune prognostic index in patients with metastatic renal cell carcinoma receiving nivolumab plus ipilimumab treatment remains unclear. This study examines the association between lung immune prognostic index and outcomes in this setting.
Methods
We retrospectively evaluated 156 patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab at eight institutions. We assessed the associations between pre-treatment lung immune prognostic index and survival outcomes including progression-free survival, second progression-free survival (PFS2), cancer-specific survival and overall survival.
Results
Patients were classified into good (n = 84, 54%), intermediate (n = 52, 33%) and poor (n = 20, 13%) lung immune prognostic index groups. Progression-free survival did not significantly differ between lung immune prognostic index groups, but there was significant difference in PFS2, cancer-specific survival and overall survival. In multivariable Cox proportional hazard analyses, high pre-treatment lung immune prognostic index was a significant predictor of poor PFS2 (vs. good group, intermediate group: P = 0.01 and poor group: P = 0.04) and poor overall survival (vs. good group, intermediate group: P = 0.01 and poor group: P < 0.01). Moreover, the patients with poor lung immune prognostic index had significantly poorer cancer-specific survival than those with good LIPI (P < 0.01).
Conclusions
High pre-treatment LIPI is suggested by our results to be a significant independent predictor of poor prognosis in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Wakayama Medical University, Wakayama, Japan.
- Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
- Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Japan.
- Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
- Department of Urology, Nara Medical University, Kashihara, Nara, Japan.
ORCID-Profile: Shimpei Yamashita, Shuzo Hamamoto, Makito Miyake
Zitieren
APA
Yamashita, S., Hamamoto, S., Furukawa, J., Fujita, K., Takahashi, M., Miyake, M., Ito, N., Iwamoto, H., Kohjimoto, Y., & Hara, I. (2024). Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Japanese Journal of Clinical Oncology, 54(6), 722-729. https://doi.org/10.1093/jjco/hyae031
Vancouver
Yamashita S, Hamamoto S, Furukawa J, Fujita K, Takahashi M, Miyake M, et al. Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Japanese Journal of Clinical Oncology. 2024;54(6):722-729. doi:10.1093/jjco/hyae031
BibTeX
@article{Yamashita2024,
author = {Yamashita, Shimpei and Hamamoto, Shuzo and Furukawa, Junya and Fujita, Kazutoshi and Takahashi, Masayuki and Miyake, Makito and Ito, Noriyuki and Iwamoto, Hideto and Kohjimoto, Yasuo and Hara, Isao},
title = {Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab},
journal = {Japanese Journal of Clinical Oncology},
year = {2024},
volume = {54},
number = {6},
pages = {722--729},
doi = {10.1093/jjco/hyae031}
}
EUVIMED